Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2

Cell Prolif. 2011 Aug;44(4):380-90. doi: 10.1111/j.1365-2184.2011.00760.x. Epub 2011 Jun 6.

Abstract

Objectives: Non-steroidal anti-inflammatory drugs have been shown to induce apoptosis in primary B-cell chronic lymphocytic leukaemia (CLL) cells, but the molecular mechanisms that underpin this observation have not been fully elucidated. Here, we have analysed the effect two novel aspirin analogues, 2-hydroxy benzoate zinc (2HBZ) and 4-hydroxy benzoate zinc (4HBZ), on primary CLL samples.

Materials and methods: Cytotoxic effects of 2HBZ and 4HBZ were analysed in primary CLL cells derived from 52 patients, and normal B- and T-lymphocytes. Mechanisms of action of these agents were also elucidated.

Results: Both analogues induced apoptosis in a dose-dependent and time-dependent manner. Apoptosis was associated with activation of caspase-3 that could be partially abrogated by the caspase-9 inhibitor (Z-LEHD.fmk). Importantly, both agents demonstrated preferential cytotoxicity in CLL cells when compared to normal B- and T-lymphocytes. In terms of their molecular mechanisms of action, 4HBZ and 2HBZ inhibited COX-2 transcription and protein expression and this was associated with upstream inhibition of transcription factor Rel A. Co-culture of CLL cells with CD40 ligand-expressing mouse fibroblasts significantly increased COX-2 expression and inhibited spontaneous apoptosis. Importantly, the most potent analogue, 4HBZ, overcame pro-survival effects of the co-culture system and significantly repressed COX-2. Finally, elevated COX-2 expression was associated with poor prognostic subsets and increased sensitivity to 4HBZ.

Conclusions: Our results demonstrate therapeutic potential of 4HBZ and are consistent with a mechanism involving suppression of Rel A nuclear translocation and inhibition of COX-2 transcription.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1 / metabolism
  • Aged
  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis
  • Aspirin / analogs & derivatives*
  • CD40 Antigens / metabolism
  • Caspase 3 / metabolism
  • Caspase Inhibitors
  • Coculture Techniques
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 Inhibitors / chemistry
  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Male
  • Membrane Glycoproteins / metabolism
  • Mice
  • Oligopeptides / pharmacology
  • Parabens / chemistry
  • Parabens / therapeutic use*
  • Salicylic Acid / chemistry
  • Salicylic Acid / therapeutic use*
  • Transcription Factor RelA / antagonists & inhibitors*
  • Transcription, Genetic / drug effects
  • Tumor Cells, Cultured
  • ZAP-70 Protein-Tyrosine Kinase / metabolism

Substances

  • Antineoplastic Agents
  • CD40 Antigens
  • Caspase Inhibitors
  • Cyclooxygenase 2 Inhibitors
  • Membrane Glycoproteins
  • Oligopeptides
  • Parabens
  • RELA protein, human
  • Transcription Factor RelA
  • benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • ZAP-70 Protein-Tyrosine Kinase
  • CD38 protein, human
  • ADP-ribosyl Cyclase 1
  • Caspase 3
  • 4-hydroxybenzoic acid
  • Salicylic Acid
  • Aspirin